• Astiva Health currently offers Medicare Advantage health plans in two heavily populated southern California counties; the company is planning to expand its operation in northern California and other states
• The company serves and supports an underserved Vietnamese-American population
• The company plans to expand its successful culturally responsive strategies to serve other ethnic populations
• Astiva Health has strategically positioned itself in a region with a dynamic and diverse population
• Astiva’s forward-thinking investment in sustainable growth aligns with evolving healthcare dynamics, ensuring the company remains resilient and transformative in meeting the diverse needs of communities

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) healthplan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs and supplemental benefits for Medicare enrollees currently located in Orange and San Diego County of California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another healthplan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Chartis, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Chartis report.

Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

For more information, visit the company’s website at www.AstivaHealth.com. 

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Israel passed the Electronic Monitoring Bracelet Law in June 2023, allowing courts to monitor abusers through electronic monitoring (EM), a practice already employed in a growing number of other countries
• SuperCom’s PureSecurity Electronic Monitoring Suite has been used in other countries to monitor domestic violence offenders, including use as part of Romania’s first electronic monitoring program
• The company is seen at the forefront when it comes to advances in EM technology for domestic violence applications

In late June 2023, the Israeli government passed the Electronic Monitoring Bracelet Law, which National Security Minister Itamar Ben-Gvir proposed. The purpose of the law is to allow the court to impose monitoring of abusers through an electronic monitoring solution, which keeps the person under surveillance and monitored in real time. Israel is not the first country to use electronic monitoring devices for domestic violence offenders. Countries including Romania, Sweden, and the United States, have all used this technology to help prevent additional domestic violence cases.

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions, providing advanced safety, identification, and security products and solutions to governments and private and public organizations, is at the forefront of domestic violence electronic monitoring technology advances. Located in Tel Aviv, Israel, SuperCom is positioned to provide the proposed monitoring solutions to the local government in Israel, as it has to other governments worldwide.

Other countries have deployed SuperCom’s PureSecurity Electronic Monitoring Suite for domestic violence monitoring. The PureSecurity Suite is an electronic monitoring and tracking platform that features a comprehensive set of innovative features, including:

• Advanced anti-tampering mechanisms
• Multi-factor biometrics
• Newest location technology and sensors
• Practically limitless historic data
• Seamless 3rd party API integration
• Ultra-lightweight ankle bracelet with proprietary energy efficiency algorithms

SuperCom’s PureSecurity Suite has been deployed in several countries – including use as the first electronic monitoring project in Romania, announced in August 2022. “We are excited with the execution of this contract; it further validates our strategy to scale up operations to accelerate growth and improve public safety in more nations worldwide,” said SuperCom’s President and CEO, Ordan Trabelsi, during the project’s first phase (https://ibn.fm/Qd9nw). “We look forward to supporting Romania’s public safety efforts and bringing them the many benefits of SuperCom’s proprietary EM technology. It is an honor to take part in this national initiative by building the necessary infrastructure and deploying Romania’s first EM program.”

Since the successful implementation of the first phase, the Romanian government has issued a second order for SuperCom’s services, valued at approximately $7.1 million. Trabelsi said that with this additional order, SuperCom continues to solidify its position as a leader in the electronic monitoring market and as a trusted partner to governments worldwide (https://ibn.fm/5AGwx). “With a pipeline of over $200 million of potential projects, a strong base of recurring revenues, and high win rates in competitive tenders, we continue to execute our global growth strategy.”

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions. The company’s proprietary PureSecurity Suite of hardware, connectivity, and software components is the foundation for its criminal justice services, including domestic violence monitoring. Each of SuperCom’s electronic monitoring services is custom-tailored to meet the needs of the client requesting them – ensuring that individual needs are addressed by the unit commissioned.

With the passing of Israel’s new electronic monitoring law, defendants in domestic violence cases are subject to electronic monitoring if the court finds them dangerous or if they have been convicted of domestic violence in the past. SuperCom offers proprietary EM solutions that support a wide array of programs such as GPS Monitoring, house arrest, domestic violence, and more. SuperCom’s offering includes a diverse portfolio of monitoring solutions, including the PureOne, PureTrack, PureProtect, PureCom, Purebeacon, and PureTag products.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• The 2023 Nobel Prize in Chemistry, awarded to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, recognizes the power of nanotechnology
• Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm, while nanotechnology is the technology that utilizes nanoscience in practical applications
• The applications of nanotechnology are wide-ranging, from industrial-scale catalysis and modern electronics to precision medicine and quantum technology
• Clene Inc., a late clinical-stage biopharmaceutical company, has applied nanotechnology alongside other science concepts in the development of catalytically active nanocrystals
• The catalytic activities of the nanocrystals drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells

The Royal Swedish Academy of Sciences (“the Academy”), which is responsible for awarding Nobel Prizes in Chemistry and Physics, decided to award this year’s Nobel Prize in Chemistry to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, nanometer-sized semiconductor crystals that bring colored light to TV screens with Q-LED technology (https://ibn.fm/shWLi). The 2023 Nobel Prize in Chemistry recognizes the power of nanotechnology and the importance of quantum dots in nanotechnology.

Although the origins of nanotechnology predate the trio of laureates, their work was “part of the earliest wave of modern nanotechnology where researchers began putting breakthroughs in material science to practical use,” according to Andrew Maynard, Professor of Advanced Technology Transitions at the Arizona State University (https://ibn.fm/oiB0C). The Academy agrees, noting in a document that gives the scientific background of the 2023 Nobel Prize in Chemistry that “The discovery of quantum dots, and the ability to synthesize such materials with high accuracy but relatively simple chemical methods, was an important step in the development of nanoscience and nanotechnology…  it inspired many chemists to engage in [nanoscience]” (https://ibn.fm/ldISn).

Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm, while nanotechnology is the technology that utilizes nanoscience in practical applications (https://ibn.fm/q1DzU). Nanotechnology is about harnessing properties that scientists in the field of nanoscience discover to improve the performance of materials or enable entirely new applications. Presently, the applications of nanotechnology range from industrial-scale catalysis and modern electronics to precision medicine and quantum technology. And with research ongoing, new applications and discoveries are a feasible possibility, as Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, has demonstrated.

Clene and its wholly owned subsidiary, Clene Nanomedicine Inc., united concepts from electrochemistry, material science, plasma and quantum physics, biochemistry, and, most importantly, nanotechnology to create and refine a proprietary electro-crystallization method that results in clean-surfaced, highly faceted, and biologically catalytically active nanocrystals. The catalytic activities drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells.

Based on these beneficial capabilities, Clene is developing a broad and deep pipeline of novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics aimed at addressing a range of diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease.

As the 2023 Nobel Prize in Chemistry continues to spotlight nanotechnology and particularly quantum dots, one thing stands out that perhaps also shines this light on Clene’s nanoparticles. Though markedly different, quantum dots and Clene’s catalytically active nanocrystals share one fundamental trait: some of their individual properties can be tuned using the same single parameter – the particle’s size. Just as the different sizes of quantum dots cause them to emit various colors, the sizes of the nanocrystals impact their catalytic activities, according to Clene. (In addition to the size factor, the catalytic activities of the nanocrystals are also determined by their shape, faceting, and chemical composition.)

“Our CSN platform has demonstrated flexibility in its ability to make, for instance, both pure gold and gold-platinum nanocrystals of consistent and reproducible shapes and sizes, in addition to making solutions of ionic zinc and silver. Because of the ease with which new single elemental and composite nanocrystals can be made of varying shapes and sizes using our proprietary techniques, we plan to continue developing a wide range of CSN therapeutics to generate a deep pipeline of drug candidates to treat a host of different diseases,” the company explained in its 2022 annual report (https://ibn.fm/JWVYB).

So far, Clene has developed CNM-Au8, its lead drug candidate, which is an oral suspension of clean-surfaced, catalytically active gold nanocrystals. The company is investigating CNM-Au8 as a disease-modifying treatment for ALS, MS, and Parkinson’s disease. Other products include CNM-ZnAg, a proprietary zinc-silver ionic solution; CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions; and CNM-PtAu7, a gold-platinum nanotherapeutic (https://ibn.fm/JNFh3).

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• GEMXX reported significant growth in its Q2 2023 revenue and net income, with the company anticipating additional growth and increased production of its gold assets in 2024
• GEMXX, in partnership with Crazy Horse Mining Inc., proved the commercial viability of the Snow Creek gold mine and is looking to similarly prove the viability of the Rosella Creek gold asset in 2024
• For the balance of 2023 and into 2024, the company is targeting additional acquisitions, more mine production, and more revenues, and plans to expand gemstone and jewelry production by 300% in 2024

GEMXX (OTC: GEMZ), a company specializing in gold mining and production and distribution of jewelry and gemstones on a global scale, supplying its own mined resources, shared positive financial results for the second quarter of fiscal 2023, ended September 20, 2023, and provided business and mining updates. Key highlights included a near-60% year-over-year increase in its net income to $212,526 from $132,842 in the same period last year and revenue growth YTD to $418,115 in the just-ended quarter up from $388,717 in Q2 2022 and $183,673 in Q1 2023. The company reported that its total assets had increased to $20,116,566, up from $18,400,825 in Q2 2022, and that its long-term debt remains at $0.00 (https://ibn.fm/RVX6m).

“We are pleased with the performance of the company, and we are excited for the anticipated growth in shopping television sales and 2024 production of our gold assets. We look forward to updating shareholders as each new project comes online. Everything the company has planned is focused on driving shareholder value,” conveyed Jay Maull, GEMXX CEO.

GEMXX’s focus on driving shareholder value saw the company complete the acquisition of 50% of Crazy Horse Mining Inc. (“CHMI”), a Canadian company with significant gold assets, including its mineral assets located in British Columbia, Canada, according to a May 23 news release (https://ibn.fm/iqrJ7). CHMI’s principal gold exploration assets include the Snow Creek and Rosella Creek projects, as well as additional options on mining claims located in British Columbia. The Snow Creek project covers 498 acres, of which about 80% is mineable, while the Rosella Creek project occupies an area of 240 acres, with approximately 90% being mineable.

“The acquisition of the Snow Creek and Rosella Creek gold asset portfolio enhances the company’s long-term asset expansion plan and helps to de-risk revenues, but most importantly, it complements our Ammolite production with the world’s most sought-after commodity, GOLD” said Maull of the acquisition.

Since May, GEMXX has made several strides and achieved significant milestones, which the company documented in a November 7 mining update (https://ibn.fm/5qx03). The update emphasized the company’s continued commitment to maintaining control over every stage of its production and operation, from gold mining and gemstone production to jewelry manufacturing and worldwide distribution, stressing that the company has been able to continue its expansion efforts while avoiding long-term debt.

According to the update, GEMXX, in partnership with CHMI, proved the commercial viability of the Snow Creek gold mine, having successfully completed gold production at the test site for the 2023 mining season. As part of the test and mining exercise, a total of 31,200 cubic yards of gold-bearing ore was processed, yielding 0.929 ounces per 100 cubic yards. These commercial production results met all expectations, according to the company, proving that the project is worth scaling up in 2024 (https://ibn.fm/8oVqF).

Accordingly, GEMXX has included in its 2024 objectives plans to upscale the gold mine operation with the aim of tripling production at the Snow Creek Mine site. In the meantime, however, GEMXX is compiling all test and mining results from the 2023 mining season in order to use them as part of the information required to complete an S-K 1300-compliant resource report.

The November 7 update also highlighted that GEMXX and CHMI are working closely to maximize resources and equipment to operate both the Snow Creek and the Rosella Creek gold mines in 2024. In 2024, the test plant used at the Snow Creek site will be transferred to Rosella Creek to prove the commercial viability of the project.

In addition, through the update, GEMXX notified investors of ongoing preparations to open an Ammolite mine on the company’s south block, possibly in early 2024, and plans to expand gemstone and jewelry production by 300% in the coming year. Moreover, the company is working to complete due diligence and the 50% acquisition of the historic Yukon Gold Property by the end of the 2023 calendar year. The NI 43-101 Resource Report, akin to the S-K 1300 report, completed by parties unaffiliated with GEMXX, confirms that the property holds 2,210,660 ounces of proven gold resources (https://ibn.fm/lI8A5).

For the remainder of 2023 and into 2024, the company is focused on expansion and adding shareholder value, which means additional acquisitions, more mine production, and more revenues.

Those interested in becoming a GEMXX investor are encouraged to visit the company’s investor page (https://ibn.fm/XKt4s) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com/investors.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• SenesTech, experts in animal fertility control, posted a 44% YOY revenue growth for Q3 2023
• Gross profit also saw 49% growth from $122,000 in 2022 to $175,000 in 2023
• The growth was attributed to the company’s primary initiatives to drive sales, improve product quality, and expand product options
• The company looks to greatly accelerate growth with the launch of its Evolve Soft Bait, key to opening the huge professional rodent control market, and the first and only soft bait developed to control pest populations through technology that targets the population where it starts, without poisons

SenesTech (NASDAQ: SNES), an animal fertility control innovator and the inventor of the only EPA-registered contraceptive for male and female rats, announced its financial results for the third quarter of the 2023 financial year (“Q3, 2023”) on November 9, 2023. Of note was the 44% year-over-year (“YOY”) growth in revenue, primarily attributed to the company’s initiatives to drive sales, improve product quality, and expand product options.

“We accelerated our growth trajectory during the third quarter with strong 44% year-over-year growth in revenues driven by the initiatives we have undertaken to drive sales, improve our product quality, and expand our product options,” noted Joel Fruendt, SenesTech’s President and CEO (https://ibn.fm/e4qRg).

Revenue for Q3 2023 stood at $360,000, up from $250,000 in Q3 2022. Gross profit also saw a 49% growth, from $122,000 in 2022 to $175,000 in 2023. Sales growth was driven by the increases in every key market segment, including but not limited to commercial, agribusiness, zoos, and sanctuaries. SenesTech’s e-commerce platform also saw a decent return on marketing investment, a positive uptick following the successful reconfiguration of operations earlier in the year.

SenesTech plans to capitalize on this growth and accelerate it in the coming months and years to create value for its shareholders and stamp its position as an industry leader. The company is currently launching its Evolve Soft Bait, the first and only soft bait developed to control pest populations. It is a healthy addition to its growing product line, which currently comprises Ultimate, Isolate, and Elevate, pest bait systems delivered in liquid form. This foray into non-liquid baits, represented by Evolve, is key to tapping the vast professional market by offering a non-liquid bait form that fits the preferences of rodent control specialists.

With each product offering or iteration, SenesTech has pushed the envelope, providing more value to consumers and differentiating itself from its industry peers with unique technology. For instance, when it introduced Elevate in 2022, it offered a targeted approach to above ground rat infestations with easier deployment in rafters of barns, storage and manufacturing facilities, attics, and granaries.

The company looks to initially focus on commercial markets and key distributors. In addition, the company looks to explore e-commerce providers like Amazon and big box retailers, bringing the product closer to its target consumers. SenesTech is optimistic that this offering will yield significant additional growth.

“We expect this growth to further accelerate as we launch our Evolve Soft Bait, the first and only soft bait developed to control pest populations using a breakthrough technology that targets the rat population where it starts, by restricting fertility through nonlethal methods,” noted Mr. Fruendt.

Their most recent addition, Evolve, is specifically designed to be highly palatable to rats and easy to deploy. It also offers diverse placement in different environments, allowing for its application in parks, sports venues, food processing facilities, subways, agribusiness, residential locations, and recreational facilities. With SenesTech’s distribution, paired with the product’s competitive pricing compared to rodenticide alternatives, the company looks to carve out a significant market share and grow its revenues even further as time progresses.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• This week’s New to the Street episode revolves around a recent cyberattack targeting ICBC (Industrial and Commercial Bank of China Limited), the world’s largest bank
• ICBC and its subsidiary, ICBC Financial Services, fell victim to a crippling ransomware attack, resulting in a system shutdown
• Sekur’s secure email solution operates exclusively on the company’s wholly-owned servers, safeguarding both senders and recipients, even if the latter is not a Sekur subscriber

New to the Street TV, a leading financial and business news show, recently sat down with Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) CEO Alain Ghiai to discuss the recent cyberattack on one of China’s largest financial institutions. The Weekly Hack segment brings Mr. Ghiai, TV co-host, and multimedia journalist Ana Berry to discuss security and privacy issues sweeping the nation.

The focal point of this episode revolves around a recent cyberattack targeting ICBC (Industrial and Commercial Bank of China Limited), the world’s largest bank (https://ibn.fm/hY95q). ICBC and its subsidiary, ICBC Financial Services (“FS”), fell victim to a crippling ransomware attack, resulting in a system shutdown. The consequences were dire, with approximately $9 billion worth of US Government Bond trades and other financial transactions unable to settle, causing significant turbulence in the financial markets.

Mr. Ghiai, drawing on his extensive expertise, speculates that the cyberattack compromised the bank’s corporate email system, paving the way for the ransomware intrusion. What struck him as unusual was the shift of executives to using Gmail accounts for communication when the corporate system was offline, underscoring the inherent cybersecurity risks associated with open-platform, free Big Tech email services.

Mr. Ghiai takes the opportunity to share the origins of Sekur, a company he founded a decade ago in response to the Sony Pictures Entertainment hack. Since its inception, Sekur has rolled out an array of subscription-based products tailored for individuals and businesses. Notably, SekurMail, featuring the innovative SekurSend/SekurReply feature, significantly reduces the likelihood of a cyber breach.

This secure email solution operates exclusively on Sekur’s wholly-owned servers, safeguarding both senders and recipients, even if the latter is not a Sekur subscriber. Importantly, Sekur refrains from third-party platforms or software, ensuring all offerings are encrypted and closed-looped.

Another vital component of Sekur’s comprehensive privacy solutions is SekurVPN, which offers users a Swiss VPN IP address, effectively concealing their online presence in Switzerland. This strategic approach virtually eradicates the tracking of users’ web traffic. All electronic communications by Sekur subscribers are routed through the company’s proprietary data servers in Switzerland, a nation known for having the strictest privacy laws globally.

Sekur is offering viewers an exclusive opportunity to subscribe using the PROMO CODE: PRIVACY, which grants a 15% discount on all products and bundled services for the next five years to demonstrate its commitment to privacy. It is essential to emphasize that Sekur never engages in data selling, never requests phone numbers, abstains from utilizing third-party cloud applications, and refrains from tracking web traffic.

For more information, visit the company’s website at www.SekurPrivateData.com or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• GEMXX Corporation is unique as a jewelry maker with important Canadian mining assets, supporting its mine-to-market operations dealing in gold and the rare Ammolite gemstone
• Amid recent market fluctuations, gold continues to maintain a strategic profile as an investment safe haven, with consumption continuing at a historic pace
• GEMXX is riding high on recent “explosive” revenue growth and a no long-term debt position, looking forward to fulfilling select goals to improve its overall production, uplisting to a major exchange and aggressively seeking out strategic acquisitions to add revenue and / or reduce its costs
• A new NetworkNewsAudio News Podcast and a corresponding news editorial highlight the company’s competitiveness against other players in the precious metals sector

The World Gold Council (“WGC”) recently reported that global gold demand slipped in year-over-year purchase totals from last year’s Q3 record highs, but central bank consumption continues at a “historic pace” and when over-the-counter (“OTC”) purchases plus stock flows are added into the equation, demand was actually up 6 percent over the corresponding 2022 period, according to Forbes (https://ibn.fm/hZJgz).

The report shows gold continues to maintain its strategic investment benefit as a safe haven that provides stability during uncertain economic times. GEMXX (OTC: GEMZ) has enjoyed significant growth during the recent conditions, “exploding past startup phase and achieving global growth in mere months” as it seeks to leverage a vertically integrated mine-to-market position, as an enterprise that specializes in producing gold and gemstone jewelry from its own land resources (https://ibn.fm/I4dsx).

“We have made considerable strides in the past year and continue to post positive net revenues,” GEMXX CEO Jay Maull stated in and Aug. 24 company news release (https://ibn.fm/chK2W). “We have also reduced our total long-term liabilities to $0.00, which is a remarkable achievement. One that tangibly reinforces our ambitious commitment to building strategic partnerships, the pursuit of smart growth and expansion plans, introduction of new complementary product lines, and our focus on increasing shareholder value.”

GEMXX was recently featured in a NetworkNewsAudio News Podcast and a corresponding news editorial highlighting the company’s competitiveness against other players in the precious metals sector (https://ibn.fm/N6Bpk).

The company reported a “whopping” 170 percent YOY increase in annual revenues for the fiscal year ending in 2022, the editorials state, it has no long-term debt, and is adding owned assets to its balance sheet after the inferred value of the gold at the company’s Snow Creek and Rosella Creek mines in British Columbia, Canada, has been confirmed by Aurora Geosciences.

“For the balance of 2023 and into 2024, the Company is focused on expansion and adding shareholder value. That means more acquisitions, more mine production and more revenues,” GEMXX states in an Oct. 31 news release (https://ibn.fm/UDMUf).

Its targets for the coming year include completing its planned 50 percent acquisition of the Yukon Gold Project in Canada’s Yukon Territory with 2.2 million ounces of proven gold resources and the potential for a yield of up to 4 million ounces; launching a pilot mine on the Yukon site; bringing its Ammolite gem mine in Alberta into full production; upscaling the Snow Creek operation and moving its test plant to Rosella Creek; completing S-K 1300-compliant resource reports on already owned assets; and completing audits for the OTCQX exchange in preparation for uplisting to the New York Stock Exchange or NASDAQ.

“We look forward to updating shareholders as each milestone … is met. Everything the company has planned is focused on driving shareholder value,” Maull stated in the news release.

GEMXX is the only publicly traded Ammolite gemstone company in the world and is led by an executive team with over 160 years of combined experience. That experience allowed the company to double its production volume to meet demand during the pandemic, continuing to grow its operations while remaining cash flow positive.

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• During the live type-B meeting, PaxMedica discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One HAT, also called African Sleeping Sickness
• The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT
• PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024
• The global ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced the completion of a type-B meeting with the Food and Drug Administration. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated (https://ibn.fm/m7n6V).

Suramin sodium was created as a treatment for people who contracted a deadly form of Human African Trypanosomiasis (“HAT”), a form of sleeping sickness. The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT.

The intention for PaxMedica is to sell the drug’s approval PRV (Priority Review Voucher) for suramin for HAT to big pharma companies and raise the necessary funding needed to explore suramin for use in ASD treatments. The first step in approving suramin for HAT was the type-B meeting with the FDA. The company anticipates the next steps will drive the future of their important research and development efforts.

PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024. Most of the work to achieve this important milestone will focus on completing the production of commercial lots of PAX-101 under CMC regulatory guidelines, which are underway now and scheduled to conclude in the first half of 2024.

“This is an important turning point for our young company, and we are very pleased with the guidance the FDA provided us in this meeting,” said Howard Weisman, CEO and Chairman of PaxMedica. “We look forward to urgently completing the necessary steps in the coming months to clear the path to submit our first NDA for PAX-101.”

According to Fortune Business Insights, the global ASD therapeutics market was valued at $1.93 billion in 2022. This market is projected to grow at a CAGR of 7.9%, resulting in a value of $3.42 billion by 2030. According to a 2020 CDC report, it is estimated that 1 out of 54 children have been diagnosed with ASD in the United States – the growing prevalence of the disease coupled awareness about the condition and available treatments are key factors expected to with the rising drive the ASD therapeutics market growth (https://ibn.fm/1Ylzn).

The company’s lead programs are focused on ASD (Autism Spectrum Disorder). Currently there is no approved pharmacologic treatment that effectively targets ASD’s cause as well as symptoms. The only treatments available on the market are designed to address symptoms of the condition rather than targeting the pathophysiology itself. PaxMedica is on a promising path to address these critical unmet medical needs and bring hope to millions.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• Strategic metals supply chain innovator Ucore Rare Metals Inc. has developed a proprietary technology it expects to improve rare earth element (“REE”) processing, and is preparing for commercial use of its solution
• The REE supply chain has become a matter of concern to Western governments as well as private industry because of the tremendous market dominance enjoyed by the People’s Republic of China and fears China will exploit that dominance with increasing export restrictions
• Ucore is currently demonstrating the ability of its RapidSX(TM) REE processing solution to match and / or exceed the capacity of industry-standard CSX processing technology while improving on its costs and ease of use
• The company has acquired property in Louisiana it intends to develop during the next year into a commercial-use REE processing center, using American REE feedstock

China’s recently announced controls on reporting exports of rare earth metallic elements (“REEs”) used strategically for permanent magnets in computerized products is the latest salvo in the ongoing trade war between the large Asian nation and the United States, prompting further emphasis on the need for Western independence from China-based supply chains.

Strategic metals enterprise Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is a company operating in Canada and the United States to improve the production of REEs in the Americas and reduce dependence on supply chains that flow through China.

Since China began taking advantage of inexpensive labor to affect the price of REE supply decades ago, U.S. production of REEs has dwindled to the point that only one REE mine is operating in the United States, and it sends its ore to China for processing that separates the desired elements from their host ore.

China controls 60 percent of mined REE resources in the global market, 87 percent of the mid-stream processing and 90 percent-plus of the downstream product creation, according to Ucore CEO Pat Ryan (https://ibn.fm/1zGaG).

The controls announced earlier this month require Chinese REE exporters to report their shipment orders to the government beginning Dec. 1 and continuing through October 2025. Although no restrictions accompany the reporting requirement, the policy is regarded as a reaction to U.S. restrictions on exports of high-end semiconductors and a potential precursor to limits on international REE trade (https://ibn.fm/W71I3).

Such a possibility was further underscored by China’s decision in late November to require exporters of its high-grade graphite — another mineral strategically critical to the manufacture of computerized products and clean energy resources — to apply for government approval, allowing authorities to pick and choose which companies will be able to import Chinese graphite if it chooses, according to a Washington Post report (https://ibn.fm/oyQIO).

Ucore’s proprietary RapidSX(TM) REE processing solution is the key to its strategy to promote Western supply chain independence from Chinese controls. The company has been using RapidSX(TM) to process REEs in head-to-head testing at a Canadian facility against the standard CSX separation technology used globally throughout the industry, and Ucore is preparing to launch construction of a facility in the United States that will use RapidSX(TM) for commercial REE processing.

The U.S. and Canada national governments have both announced they will provide millions of dollars in funding to help Ucore achieve its goals, given REEs’ strategic importance to national clean energy policies and the products used in national defense infrastructure.

The reporting requirements for graphite exports are “a warning shot for sure,” Emily Benson, a senior fellow at the Center for Strategic and International Studies focusing on trade and technology, told the Washington Post for its report. “Will they really bite? Probably not, but it’s a sign that the more tools you use to combat China economically, the greater the risk of retaliation.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Mountain Top Properties is seeking to capitalize on the Hamptons real estate market through its maiden investment fund, Mountain Top Capital Fund I LLC
• In conjunction with renowned contractor, On Site Builder Construction, the fund will seek to acquire, build, renovate, and resell homes in the exclusive Long Island enclave
• Mountain Top Capital Fund have announced plans to raise up to $75 million to fund its commercial endeavours, with a significant amount of debt capital already secured to fund operations
• Brokers say that despite several slowing factors, the luxury market are still bidding and buying the Long Island beach homes

Memorial Day weekend marks the traditional opening of the Hamptons summer season, with thousands of visitors making the journey to one of the world’s most famous summertime destinations in an array of vehicles, boats and jets. Those arriving at the wealthy cluster of seaside enclaves on the eastern tip of Long Island are likely to encounter some of the grandest and most luxurious homes on the eastern seaboard, properties that have historically been the playground of America’s elite – and commanded prices commensurate to their relative grandeur.

Mountain Top Properties (OTC: MTPP), a diversified real estate holding company focused around acquiring, marketing and operating assets through its wholly owned affiliates has now sought to revolutionize hitherto exclusive Hamptons real estate market, through subsidiary, Mountain Top Realty Inc. The managing partner of Mountain Top Properties’ maiden real estate fund focused on residential redevelopment within the Hamptons’ exclusive beachfront communities, Mountain Top Realty Inc. has partnered with On Site Builder Construction Co. Inc., as their design partner in their ambitious endeavour (https://ibn.fm/MTPP).

Helmed by Joseph Kelley, On Site Builder Construction have gained a well-earnt reputation for building some of the Hamptons’ highest quality homes over the past four decades spanning a broad plethora of architectural styles – ranging from classic homes through to ultra-modern, glass-encased seaside mansions. Having built over 60 homes in the seaside retreat, Kelley and On-Site Builder Construction have the distinction of being the original builder for the Hampton’s most expensive properties in both, 2019 and 2022 – the latter at a remarkable $118,500,000 price point. Now and going forward, Mountain Top and On Site Builder Construction’s partnership will seek to leverage upon Joseph Kelley and team’s reputation and technical know-how within the Hamptons real estate market to make the shift from one-off, customized homes through to the provision of finished, turnkey properties to prospective buyers.

Through its Mountain Top Capital Fund I, Mountain Top Realty has sought to raise $75 million to acquire, renovate and remarket homes in the Hamptons; thus far, the fund has already received debt capital commitments amounting to 70 percent of their anticipated real estate acquisition costs, as well as a further 100 percent of the planned construction costs – and will look to deploy $10 million in the future to leverage strategic waterfront opportunities within the exclusive enclave.

As coveted as the Hamptons real estate may seem, the island’s housing prices hit an all-time high due to the stinginess of the market. The average price of a home in the Hamptons hit a record $3 million in the first quarter, due to the lack of homes available for sale, eventually leading to a drop in total deals, with sales volume down 57% in the first quarter (https://ibn.fm/UyIqg). Though not all is totally doubtful, as the high ends of the Hamptons market seem virtually “unfazed”. This luxury market – consisting of the top 10% of sales – broke multiple records during the first quarter, with the average luxury price surging 33% to $16.1 million, according to Jonathan Miller, CEO of Miller Samuel.

Brokers also added that many of the of the current listings are not priced right. With there being more interest from buyers than there are homes available in the Long Island community, Mountain Top Properties aims to turn this shortage around as sales are hoped to pick back up as more homes become available.

For more information, visit the company’s website at www.Mountain-Top-Properties.com.

NOTE TO INVESTORS: The latest news and updates relating to MTPP are available in the company’s newsroom at https://ibn.fm/MTPP